4 Biotechs That Could Be Potential Acquisition Targets In 2021
Moreover, several companies in the biotech sector have taken a beating in 2020 due to the COVID-19 pandemic that has disrupted clinical studies and hurt sales of many drugs. Below we discuss companies that have a gene therapy or rare disease/rare cancer pipeline candidate in their pipeline. Moreover, stocks of these companies have not fully recovered from the stock-market crash in March 2020, suggesting attractive valuations.
BioMarin Pharmaceutical Inc. (BMRN - Free Report)
Companies that have a product portfolio/pipeline of rare disease drugs are in great demand as it is a less competitive space and the expensive treatments can bring in huge profits. BioMarin is one such drug developer. Its market cap is $15.4 billion.
BioMarin has six commercially approved rare disease drugs with some more in the pipeline. The company also has gene therapies in its pipeline. Although the company’s lead gene therapy candidate, roctavian, for treating hemophilia A received complete response letter (“CRL”) in May 2020, the company believes that the candidate will receive an approval following availability of required data. The CRL asked for two-year follow-up data from the phase III study evaluating it which will be available late next year. Progress toward its potential approval may attract acquisition offers.
The company’s stock is up 5.6% so far in 2020. BioMarin has a Zacks Rank #3 (Hold).
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote
uniQure N.V. (QURE - Free Report)
This company is a promising player in the gene therapy space. It is engaged in creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration, focused on cardiovascular diseases, with Bristol Myers-Squibb. The company’s lead candidate AMT-061, an experimental AAV5-based gene therapy incorporating the FIX-Padua variant, is being evaluated in the phase III HOPE-B pivotal study for the treatment of patients with severe and moderately severe hemophilia B.
Disclaimer: Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web ...
more
Comments
